Edgewise Therapeutics, Inc. (EWTX) — 8-K Filings

8-K Filings (18)

• Edgewise Therapeutics Files 8-K on Officer/Director Changes — Nov 20, 2025 Risk: medium
  Edgewise Therapeutics, Inc. filed an 8-K on November 20, 2025, reporting on the departure of directors or certain officers, election of directors, appointment o
• Edgewise Therapeutics Files 8-K on Director Changes and Compensation — Nov 10, 2025 Risk: low
  On November 10, 2025, Edgewise Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The f
• Edgewise Therapeutics Files 8-K on Financials — Aug 7, 2025 Risk: low
  Edgewise Therapeutics, Inc. filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition. The filing includes financial statem
• Edgewise Therapeutics Files 8-K — Jun 26, 2025 Risk: low
  Edgewise Therapeutics, Inc. filed an 8-K on June 26, 2025, reporting on other events and financial statements. The filing does not contain specific financial fi
• Edgewise Therapeutics Files 8-K on Financials — May 8, 2025 Risk: low
  Edgewise Therapeutics, Inc. filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition. The filing includes financial statement
• Edgewise Therapeutics Schedules Annual Meeting, Seeks Director & Auditor Approval — Apr 2, 2025 Risk: low
  Edgewise Therapeutics, Inc. filed an 8-K on April 2, 2025, to report on an upcoming Annual Meeting of Stockholders scheduled for May 15, 2025. The company is se
• Edgewise Therapeutics Files 8-K on Financials — Mar 3, 2025 Risk: low
  Edgewise Therapeutics, Inc. filed an 8-K on March 3, 2025, reporting on its results of operations and financial condition. The filing includes financial stateme
• Edgewise Therapeutics Appoints New CMO, Adds Directors — Jan 22, 2025 Risk: medium
  Edgewise Therapeutics, Inc. announced on January 8, 2025, the appointment of Dr. Sarah Boyce as Chief Medical Officer and the election of Dr. Boyce and Mr. Davi
• Edgewise Therapeutics Files 8-K — Dec 16, 2024 Risk: low
  On December 16, 2024, Edgewise Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other events, along with fina
• Edgewise Therapeutics Files 8-K on Financials — Nov 7, 2024 Risk: low
  On November 7, 2024, Edgewise Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
• Edgewise Therapeutics Appoints New CMO, Adds Directors — Aug 12, 2024 Risk: medium
  Edgewise Therapeutics, Inc. announced on August 10, 2024, the appointment of Dr. Sarah Boyce as Chief Medical Officer and the election of Dr. Boyce and Mr. Davi
• Edgewise Therapeutics Files 8-K — Aug 8, 2024 Risk: low
  Edgewise Therapeutics, Inc. filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition, as well as financial statements and
• Edgewise Therapeutics Holds Annual Meeting, Stockholder Proposals Approved — Jun 11, 2024 Risk: low
  On June 7, 2024, Edgewise Therapeutics, Inc. filed an 8-K report detailing several key events. The company announced the results of its annual meeting of stockh
• Edgewise Therapeutics Files 8-K on Agreement Changes — May 10, 2024 Risk: medium
  Edgewise Therapeutics, Inc. filed an 8-K on May 10, 2024, reporting the entry into and termination of a material definitive agreement. The filing also includes
• Edgewise Therapeutics Files 8-K on Financials — May 9, 2024 Risk: low
  Edgewise Therapeutics, Inc. filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition. The filing includes financial statement
• Edgewise Therapeutics Files 8-K on Officer/Director Changes — May 7, 2024 Risk: low
  Edgewise Therapeutics, Inc. filed an 8-K on May 7, 2024, reporting events as of May 6, 2024. The filing pertains to the departure of directors or certain office
• Edgewise Therapeutics Reports Financial Condition on Feb 22, 2024 — Feb 22, 2024 Risk: low
  Edgewise Therapeutics, Inc. filed an 8-K on February 22, 2024, reporting on its results of operations and financial condition. The filing, under SEC File Number
• Edgewise Therapeutics Files Routine 8-K for Rule 425 Communications — Jan 19, 2024
  Edgewise Therapeutics, Inc. filed an 8-K on January 19, 2024, indicating that it is providing written communications pursuant to Rule 425 under the Securities A

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX